EUCTR2006-002477-45-DEActive, not recruitingNot Applicable
A randomized, double-blind, placebo-controlled, multicenter evaluation of the efficacy and safety of terguride tablets, administered orally for 3 months, to patients with fibromyalgia.
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
- ErgoNex Pharma GmbH
- Enrollment
- 72
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •Patients (m or f) are eligible for the study when they fulfil the following criteria:
- •·Diagnosis of fibromyalgia according to ACR criteria (1990) [Wolfe et al. 1990]
- •·Pain score ³50 mm on the patient pain VAS (100 mm)
- •·Tender point Score (TPS) ³ 11
- •·Age range from 18 to 60 y (inclusive)
- •·Body Mass Index (BMI): 18.9 < BMI < 30.0
- •·A written informed consent to participate in this study signed by the subject prior to initiation of any study specific procedure
- •·Treatment as outpatients
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- •A patient fulfilling the following exclusion criteria must not enter the study:
- •·known sensitivity to study drug
- •·suffering from relevant liver (limit for GOT and GPT: < 3-fold of upper limit of NR), kidney (limit for serum creatinine: < 1.5 mg/dL), cardiovascular (i.e. heart attack or cerebrovascular disease) or pulmonary disease (i.e. asthma or COPD)
- •·suffering from pituitary tumor representing extrasellar expansion
- •·suffering from peptic ulcers or having a history of it
- •·suffering from Raynaud syndrome or having a history of it
- •·suffering from psychosis or having a history of it
- •·suffering from a systolic blood pressure ³140 mm Hg and a diastolic pressure ³ 90 mm Hg. (Criteria in accordance with the 7th report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure (NIH Publication # 04-5230 (2004))
- •·suffering from Encephalomyelitis disseminata
- •·suffering from chronic inflammatory diseases
- •·evidence or history of drug or alcohol abuse
- •·mental impairment limiting the ability to comply with study requirements
- •·receiving therapy with agents known or likely to interact with study drug or disease:
- •- Antidepressants or SSRIs are not allowed from 6 weeks before V(-1) throughout the entire study. However, patients with substantial therapeutic benefit from such compounds should not be discontinued for study participation.
- •- Antiepileptics, Anxiolytics, Muscle relaxants or Hypnotics have to be discontinued at least 10 elimination half lives of the respective drug before V(-1); for details see section 9.4.7,
- •·participation in any clinical study or donation of blood in the period from 60 days prior to study initiation until end of study .
- •Additionally, women with child bearing potential must be excluded if:
- •·They have not used reliable contraception in the cycle before the study. According to CPMP/ICH/286/95 (modification) highly effective methods of birth control (defined by a failure rate < 1% per year) include the consistent and correct use of implants, injectables combined oral contraceptives, selected intrauterine devices (IUD), sexual abstinence or vasectomised partner The subject has to agree to continue using such highly reliable contraception during the entire study period and the cycle after the study
- •·They are pregnant or lactating. (A negative pregnancy test must be provided for all female subjects with child bearing potential at screening and on Day 0)
Investigators
Similar Trials
Active, not recruiting
Phase 1
Study on the safety of the drug runcaciguat and how well it works when given at the highest dose as tolerated by the individual patient whose kidneys are not working properly and suffering at the same time from a disease of the heart and the blood vessels and high blood sugarTreatment of cardiovascular and renal disease in patients with chronic kidney diseaseMedDRA version: 21.1Level: PTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 10038359 - Renal and urinary disordersMedDRA version: 20.0Level: PTClassification code 10001580Term: AlbuminuriaSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2019-003297-53-ESBayer AG432
Active, not recruiting
Not Applicable
A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of licarbazepine 750-2500 mg/d combined with risperidone in the treatment of manic episodes of bipolar I disorder over 6 weeksBipolar I disorder, manic and mixed episodesEUCTR2004-000113-18-HUovartis Hungaria Kft.430
Active, not recruiting
Phase 1
Phase 2b dose-ranging study of ALX-0171 in infants and young children hospitalized for RSV lower respiratory tract infectioRSV lower respiratory tract infectionMedDRA version: 20.1Level: PTClassification code 10061603Term: Respiratory syncytial virus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2016-001651-49-SKAblynx NV180
Active, not recruiting
Phase 1
A randomized, double-blind, placebo-controlled, multicenter phase III study of RAD001 adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching placebo after patients have achieved complete response with first-line rituximab-chemotherapyDiffuse Large B-Cell LymphomaMedDRA version: 19.0Level: PTClassification code 10012818Term: Diffuse large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-000498-40-HUovartis Pharma Services AG487
Active, not recruiting
Phase 1
Safety and efficacy study in patients with moderate to severe nail psoriasisModerate to severe nail psoriasisMedDRA version: 18.0Level: PTClassification code 10028703Term: Nail psoriasisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2012-005413-40-BEovartis Pharma Services AG195